Enhancing the therapeutic value of known pharmaceutical entities using unique drug delivery platforms.

Ulysses was founded by three researchers with years of antimicrobial experience in the university, in pharmaceutical industry and in California biotechnology.  In December 2005, Ulysses successfully raised its seed round, attracting new investors, the Business Development bank of Canada and the Fonds Bio-Innovation.
Ulysses is focused on new antibiotic chemistry to overcome bacterial resistance.

AngioChem is a Canadian clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases. The Company leverages a breakthrough platform technology capable of physiologically transporting molecules across the Blood-Brain Barrier and is currently the leader in this field.

Fondée en 2003 par les Drs John Fairbrother et Éric Nadeau, de la Faculté de médecine vétérinaire de l’Université de Montréal, l’entreprise dérivée Prevtec microbia inc. souhaite :

• Développer des technologies pour la prévention et le contrôle des infections bactériennes, particulièrement E. coli, dans les marchés de la sécurité alimentaire et de la production animale;
• Devenir un leader mondial dans la commercialisation et la distribution de produits alternatifs aux antibiotiques pour les infections bactériennes et la performance en production animale;
• Rendre les aliments plus sécuritaires, de la ferme a la table.
  
  

Mimetogen is developing small molecule mimetics of neurotrophins to treat diseases of both the back and front of the eye where there are currently large unmet medical needs.

The company’s neurotrophin mimetics target retinal ganglion cell protection in glaucoma; the stimulation of mucin production in dry eye; and the protection of retinal pigmented epithelial cells in retinitis pigmentosa. Additinoally, the company has discovered novel gene and protein targets to treat glaucoma.

Animal proof of concept studies have been completed for two compounds in glaucoma and four compounds in both dry eye and retinitis pigmentosa. Lead compound assessment will culminate in the first IND in 2009.

We are a “spin off” from University of Montreal, involved the manufacturing process of active pharmaceutical ingredient (API) and fine chemical in general. Soluphase is currently selling products, derived by two distinct platforms, aimed at obtaining better chemical synthesis and to facilitate chemistry in general.

We have a better approach to chemistry, than the competition by….

• By providing an economic benefit in reducing significantly the number of steps;
• By facilitating purification and increasing the purity of the final product;
• By being environmentally friendly and helping manufacturer with recycling and decontamination of fine chemicals used in traditional process.

Ceapro Inc. is a Canadian growth stage biotechnology company working with active ingredients from plants and in value-added industries. Our primary products enhance human and animal health; recently we initiated a major project in the field of bio-energy.

Associé directeur, Sciences de la vie et énergie
Managing Partner, Life Sciences & Energy
iNovia Capital

Managing Director, Life Sciences
VIMAC Ventures LLC
420 Bedford Street, Suite 240
Lexington, MA  02420

Patrick Tremblay, Ph.D

Executive-in-Residence
Pappas Ventures

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.